The global scenario is now supporting the development of modern drugs from less toxic plant products with proven medicinal properties. Each part of neem plant (Azadirachta indica A. Juss) reportedly has various medicinal properties and has been in use in many continents for centuries. Recently, a fractionated neem-leaf extract known as IRAB with reported activities against Malaria, HIV/AIDS and cancer has been developed into a drug and currently marketed in Nigeria as IRACAP®. This paper reviews the medicinal properties, clinical studies and safety concerns of this fractionated acetone-water neem leaves extract as a footstep to further studies both on the extract and/or its chemical constituents.
Introduction
Extracts from neem tree (Azadirachta indica A.
Juss) also called "dogonyaro" in Nigeria are most consistently recommended in ancient medical texts for gastrointestinal upsets, diarrhea and intestinal infections, skin ulcers and infections, and malaria (Schmutterer,1995) . India encouraged scientific investigations of neem tree as part of his program to revitalize Indian tradition and also increase commercial interest on neem (Stix, 1992) and presently some authors believe that no other plant or tree in the world has been so extensively researched or used, in all possible capacities so far. In Africa extracts from Neem leaves have provided various medicinal preparations (Ekanem, 1971 and Udeinya, 1993) . A fractionated acetone-water extract also known as IRAB has been showing safer medicinal properties (Mbah et al, 2007) . In-vitro studies with malaria-infected erythrocytes and metastatic cancer cells had earlier shown that IRAB has broadspectrum anti-cytoadhesion activity which has been beneficial in HIV/AIDS (Udeinya et al, 2004 Extraction is done using neem leaves collected in Nigeria in a mixture of acetone and water (1:1, by vol.) as described by Udeinya (1993) . Residue from the bottom layer of the crude extracts is then fractionated by standard, high-performance liquid chromatography (HPLC) (Udeinya et al, 2006) . The end product (IRAB) is a complex molecule (202 Daltons) with functional groups that include sodium salts of carboxylic acid and a non-aromatic dialcohol (Mbah et al, 2007) .
Reported medicinal actions of IRAB:
In-vitro and in-vivo studies on IRAB have revealed the following activities:
Anti-malaria:
Extracts from Nigerian neem leaves (Azadirachta indica) have been earlier reported to have anti-malarial activities (Ekanem, 1971 ), but Udeinya (1993) 
Are there any side effects or interactions?
Neem leaf extracts appear to be very safe at recommended intake levels with no significant reports of problems. Also, use of IRAB has consistently reported no adverse effects either as an anti-malaria (Udeinya et al, 2006 and 2008) or an anti-retroviral agent (Mbah et al, 2007 and Anyaehie 2009 ). Water extracts of neem leaf have been shown to decrease blood levels of chloroquine in rabbits (Nwafor et al, 2003 ) but this has not been investigated with IRAB. The use in pregnancy has also not been evaluated and thus is not yet recommended. At the time of writing, there were no well-known drug interactions with IRAB.
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Conclusion
Development of modern non-toxic drugs from neem has earlier been suggested (Biswas et al, 2002) and 
